Revolution Cancer International Molecular Tumor Board

August 13, 2022, Revolution Cancer International Molecular Tumor Board (KRAS dismantled, NSCLC)

In the August 13, 2022, the audience was treated to the PREMIER KRAS bench to bedside, and pipeline to patient discussion on the planet.   The MOST UP TO DATE KRAS DATA WAS PRESENTED, including all related August 2022 World Lung Conference data.   The Revolution Medicines pipeline was highlighted, as their multi-KRAS, SHP2, and KRAS G12C inhibitors were presented.     In a truly unprecedented fashion, KRAS inhibitor drug development considerations and concerns were detailed in the context of two stage 4 non-small cell lung cancer patients.    Thereafter, an incredible analysis of the stage 4 KRAS G12C mutated non-small cell lung cancer (NSCLC) patients was performed in the context of the COMET algorithm and treatment cartography.   All presently FDA-approved non-small cell lung cancer treatments were discussed, including the data that led to their approval.  Clinical trials in the stage 4 non-small cell lung cancer space, particularly those involving KRAS G12C, and a treatment map for the aforementioned stage 4 NSCLC patients were depicted.  Unmet needs in non-small lung cancer were emphasized, and the RCIMTB team presented new clinical trials to consider.   If that wasn't enough the RCIMTB took it up another level to discuss KRAS G12D, including the June 2022 NEJM paper depicting KRAS G12D CAR-T therapy.  Novel pancreatic cancer clinical trials were postulated.     Taking it up even more the RCIMTB team discussed KRAS G13C and KRAS Q61H mutations.   NOBODY HAS DONE WHAT WAS DONE IN THIS TUMOR BOARD OR THE TWO PRIOR RCIMTB TUMOR BOARDS.  MSK, MD Anderson, Johns Hopkins, Mayo, etc., are not doing what is being done here, but they should be.   If you don't believe that, PLEASE SEE FOR YOURSELF.   This tumor board was hosted by:   Basem S. Goueli MD, PhD, MBA (co-host):  CEO and Founder of CancerLight, Cancer Clarity, and Revolution Cancer Medical Care PLLC, medical director for 2 Xbiotech trials, full-time GENERAL hematologist/oncologist, consultant for numerous companies, writer of "The Insider's Guide to Translational Medicine" on biopharmatrend.com and "The Cancer Patients Don't Have an Expiration Date Series" on revolutioncancer.com, author and speaker of the "If You Were My Family Member" cancer patient education series on revolutioncancer.com and this channel   Janakiraman Subramanian MD (co-host): Co-Director of Thoracic Oncology at Inova Schar Cancer Institute (ISCI), and Director for ISCI Data and Analytics Research Core.   Silambarasan Maskomani Ph.D. (co-host):  Personalized healthcare ecosystem partner for Roche, where he is currently helping build a precision oncology program in India.    It featured:   Bhadresh Rami Ph.D.:  Senior Consultant and Advisor for Smagen, 15 years of drug development experience.   Ali Ucar:  CEO and co-founder of CaresolutionsUSA

Episode 2: July 30, 2022, Revolution Cancer International Molecular Tumor Board (PMV Pharma, small cell, liver)

In the July 30, 2022, the gloves came off as the spotlight was shined on p53.  The PMV Pharma pipeline, and their p53 Y220C activator, were highlighted.     Thereafter, an incredible presentation of an extensive stage small cell lung cancer patient with a p53 Y220C mutation was performed in the context of the COMET algorithm and treatment cartography.  All presently FDA-approved small cell lung cancer treatments were discussed, including the data that led to their approval.  Clinical trials in the small cell lung cancer space, and a treatment map for the patient presented were illustrated.  Unmet needs in small lung cancer were emphasized, and the RCIMTB team presented new clinical trials to consider.   If that wasn't enough the RCIMTB took it up another level to discuss NINE liver cancer patients with a unique molecular profile.  The COMET algorithm was used to develop specific treatment maps for stage 4 hepatocellular cancer (HCC) patients.  Absolutely UNPRECEDENTED CLINICAL TRIAL IDEAS were freely offered to pharmaceuticals, clinical trialists, etc.  Unmet needs were discussed in HCC, and drug development concerns surrounding p53 activators were illustrated.     NOBODY HAS DONE WHAT WAS DONE IN THIS TUMOR BOARD.  Not MSK, MD Anderson, Johns Hopkins, Mayo, etc.  If you don't believe that, PLEASE SEE FOR YOURSELF.   This tumor board was hosted by:  Basem S. Goueli MD, PhD, MBA (co-host):  CEO and Founder of CancerLight, Cancer Clarity, and Revolution Cancer Medical Care PLLC, medical director for 2 Xbiotech trials, full-time GENERAL hematologist/oncologist, consultant for numerous companies, writer of "The Insider's Guide to Translational Medicine" on biopharmatrend.com and "The Cancer Patients Don't Have an Expiration Date Series" on revolutioncancer.com, author and speaker of the "If You Were My Family Member" cancer patient education series on revolutioncancer.com and this channel   Janakiraman Subramanian MD (co-host): Co-Director of Thoracic Oncology at Inova Schar Cancer Institute (ISCI), and Director for ISCI Data and Analytics Research Core.   Silambarasan Maskomani Ph.D. (co-host):  Personalized healthcare ecosystem partner for Roche, where he is currently helping build a precision oncology program in India.    It featured:   Csaba Gajdos MD:   Professor of surgery and chair of hepatobiliarypancreatic surgery for the University of Buffalo   Omar Chohan MD:  Interventional Radiologist and Associate Director of the Radiology residency program for the University of Buffalo   Bhadresh Rami Ph.D.:  Senior Consultant and Advisor for Smagen  Ali Ucar:  CEO and co-founder of CaresolutionsUSA

Ep 1: Revolution Cancer International Molecular Tumor Board - July 16, 2022

We see your Memorial Sloan Kettering, MD Anderson, Mayo Clinic, Johns Hopkins, and Dana Farber, and raise you "The Revolution Cancer International Molecular Tumor Board".  Come watch what actually happens outside the walls of academia, and prepare to be AMAZED.  In this edition of the Revolution Cancer International Molecular Tumor Board, prepare to have your mind blown.  Learn about the incredible Daiichi Sankyo pipeline first-hand from Basem Goueli MD, Ph.D., MBA, and Janakiraman Subramanian MD.  Watch and listen as they provide you with the behind-the-scenes information you require, and educate you about a paradigm shift in breast cancer.  Dr. Goueli provides the listener with the best review of the low HER2 breast cancer space presently available.   In addition, Dr. Goueli and Dr. Subramanian talk about the likely upcoming trastuzumab duocarmazine approval, and review HER2, FGFR2, AKT, PIK3CA, HER3, and TROP2 inhibitors.   If that isn't enough Dr. Goueli, Dr. Subrmanian, and Dr. Maskomani reveal the next evolution in molecular tumor boards.  They use the COMET algorithm in cancer patient treatment cartography to develop an ideal treatment map for a patient with Stage 4, ER+, PR+, low HER, breast cancer, with FIVE PIK3CA mutations, an AKT1 mutation, and an FGFR2 mutation.  During the presentation they provide the MOST COMPREHENSIVE REVIEW of the stage 4 hormone receptor positive, lowHER2 space you will find.  In addition, they  discuss elacestrant, which is currently being reviewed for FDA approval. The Revolution Cancer International Molecular Tumor Board is unabashedly futuristic.  ou have never seen a tumor board like this. If you don't believe us, see for yourself.